| Literature DB >> 24395800 |
Vivian Wai Yan Lui1, Noah D Peyser, Patrick Kwok-Shing Ng, Jozef Hritz, Yan Zeng, Yiling Lu, Hua Li, Lin Wang, Breean R Gilbert, Ignacio J General, Ivet Bahar, Zhenlin Ju, Zhenghe Wang, Kelsey P Pendleton, Xiao Xiao, Yu Du, John K Vries, Peter S Hammerman, Levi A Garraway, Gordon B Mills, Daniel E Johnson, Jennifer R Grandis.
Abstract
The underpinnings of STAT3 hyperphosphorylation resulting in enhanced signaling and cancer progression are incompletely understood. Loss-of-function mutations of enzymes that dephosphorylate STAT3, such as receptor protein tyrosine phosphatases, which are encoded by the PTPR gene family, represent a plausible mechanism of STAT3 hyperactivation. We analyzed whole exome sequencing (n = 374) and reverse-phase protein array data (n = 212) from head and neck squamous cell carcinomas (HNSCCs). PTPR mutations are most common and are associated with significantly increased phospho-STAT3 expression in HNSCC tumors. Expression of receptor-like protein tyrosine phosphatase T (PTPRT) mutant proteins induces STAT3 phosphorylation and cell survival, consistent with a "driver" phenotype. Computational modeling reveals functional consequences of PTPRT mutations on phospho-tyrosine-substrate interactions. A high mutation rate (30%) of PTPRs was found in HNSCC and 14 other solid tumors, suggesting that PTPR alterations, in particular PTPRT mutations, may define a subset of patients where STAT3 pathway inhibitors hold particular promise as effective therapeutic agents.Entities:
Keywords: STAT3 activation; driver mutations; phosphatase mutations
Mesh:
Substances:
Year: 2014 PMID: 24395800 PMCID: PMC3903220 DOI: 10.1073/pnas.1319551111
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205